Aromasin (exemestane) Shows Some Advantages Over Tamoxifen As Adjuvant Therapy In Early Breast Cancer; First Results Of The TEAM Trial

News — By on December 17, 2008 at 2:00 am

Interim findings of the TEAM (Tamoxifen Exemestane Adjuvant Multicenter) trial reported on 11th December at the 2008 San Antonio Breast Cancer Symposium (SABCS) suggest women with early invasive breast cancer can expect fewer breast cancer recurrences and a longer time to the occurrence of distan

Please read the complete article and let us know what you think below.

Leave a Reply


Leave a Trackback